Strs Ohio Increases Stock Position in IQVIA Holdings Inc. $IQV

Strs Ohio grew its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 151,039 shares of the medical research company’s stock after buying an additional 3,851 shares during the period. Strs Ohio owned 0.09% of IQVIA worth $28,688,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Brighton Jones LLC grew its holdings in IQVIA by 244.4% in the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after purchasing an additional 2,537 shares during the period. Empowered Funds LLC grew its stake in shares of IQVIA by 102.1% in the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after buying an additional 4,915 shares during the last quarter. Sivia Capital Partners LLC bought a new position in IQVIA during the 2nd quarter valued at approximately $514,000. Wealth Enhancement Advisory Services LLC raised its stake in IQVIA by 53.0% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 20,289 shares of the medical research company’s stock valued at $3,332,000 after buying an additional 7,030 shares during the last quarter. Finally, Farther Finance Advisors LLC boosted its holdings in IQVIA by 34.0% in the second quarter. Farther Finance Advisors LLC now owns 398 shares of the medical research company’s stock worth $63,000 after acquiring an additional 101 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the transaction, the insider owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. This represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.60% of the company’s stock.

IQVIA Stock Down 1.6%

Shares of IQVIA stock opened at $235.20 on Friday. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $247.04. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. The company’s 50 day moving average is $229.10 and its 200 day moving average is $205.62. The company has a market cap of $40.05 billion, a price-to-earnings ratio of 32.26, a price-to-earnings-growth ratio of 2.43 and a beta of 1.36.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. The business had revenue of $4.10 billion during the quarter, compared to the consensus estimate of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The firm’s revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Upgrades and Downgrades

IQV has been the subject of several recent analyst reports. Mizuho set a $266.00 price target on IQVIA in a research report on Friday, January 9th. HSBC upgraded shares of IQVIA from a “hold” rating to a “buy” rating and raised their price objective for the company from $195.00 to $235.00 in a research note on Thursday, October 9th. Stifel Nicolaus upped their target price on shares of IQVIA from $234.00 to $254.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. UBS Group raised their price target on shares of IQVIA from $250.00 to $280.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Finally, Barclays set a $230.00 price objective on IQVIA in a research report on Monday, December 15th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $251.06.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.